reports
SiriusPoint Announces Date for Fourth Quarter 2025 Earnings Release
SiriusPoint Announces Date for Fourth Quarter 2025 Earnings Release HAMILTON, Bermuda, Feb. 04, 2026 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (NYSE: SPNT) (“SiriusPoint” or the “Company”) today announced that it is planning to release its fourth quarter 2025 financial results after the market close on Wednesday, February 18, 2026. The Company will also hold a conference call, including a question-and-answer session, to discuss its financial results at 8:30 am (Eastern Time) on Thursday, February 19, 2026. The webcast of the live conference call can be accessed by logging onto the Investor Re...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offeri...
Lexicon Announces Pricing of Approximately $94.6 Million Public Offering and Concurrent Private Placement THE WOODLANDS, Texas, Jan. 30, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced the pricing of its previously announced underwritten public offering of 32,000,000 shares of its common stock, par value $0.001. The shares of common stock being offered pursuant to the public offering are being offered at a public offering price of $1.30 per share. All of the shares are being offered by Lexicon. The gross proceeds from the public offering a...
SiriusPoint Announces Redemption of Series B Preference Shares
SiriusPoint Announces Redemption of Series B Preference Shares HAMILTON, Bermuda, Jan. 29, 2026 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, announced today that the Company will redeem all 8 million of its issued and outstanding 8.00% Resettable Fixed Rate Preference Shares, Series B (“Series B Preference Shares”) on February 26, 2026 (the “Redemption Date”). The redemption price payable on the Redemption Date is $25.00 per share, plus $0.49, which reflects unpaid, accrued cumulative dividends to, but exclud...
Lexicon Announces Proposed Public Offering of Common Stock
Lexicon Announces Proposed Public Offering of Common Stock THE WOODLANDS, Texas, Jan. 29, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) (“Lexicon”) today announced that it has commenced an underwritten public offering to offer and sell, subject to market and other conditions, shares of its common stock, par value $0.001. In addition, Lexicon intends to grant the underwriters a 30-day option to purchase additional shares of common stock. There can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the p...
SiriusPoint appoints John Sakakeeny as Chief Underwriting Officer of N...
SiriusPoint appoints John Sakakeeny as Chief Underwriting Officer of North America P&C Insurance HAMILTON, Bermuda, Jan. 28, 2026 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced the appointment of John Sakakeeny as Chief Underwriting Officer of North America P&C Insurance, effective February 2, 2026. Mr Sakakeeny will report to Patrick Charles, Head of North America Insurance, and Anthony Shapella, Group Chief Underwriting Officer. He will be responsible for providing strategic leadership to...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27,...
Lexicon Pharmaceuticals to Ring the Nasdaq Closing Bell on January 27, 2026 to Celebrate 30th Anniversary THE WOODLANDS, Texas, Jan. 23, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the Company will ring the Nasdaq Stock Market Closing Bell on Tuesday, January 27, 2026. The event will commemorate Lexicon’s 30th anniversary as a biopharmaceutical company building a differentiated pipeline of oral small-molecule therapies for people living with serious cardiometabolic diseases and chronic neuropathic pain. “In its early days, Lexicon was focused on pioneering a deeper understa...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting wi...
Lexicon Pharmaceuticals Announces Successful End-of-Phase 2 Meeting with FDA For Pilavapadin in the Treatment of Diabetic Peripheral Neuropathic Pain – No objections raised by FDA to advancement of pilavapadin into Phase 3 development utilizing two-arm registrational studies of 10 mg daily dose compared to placebo – THE WOODLANDS, Texas, Jan. 21, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the successful completion of the End-of-Phase 2 (EOP2) Meeting with the U.S. Food and Drug Administration (FDA) for pilavapadin in diabetic peripheral neuropathic pain (DPNP). During the ...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the...
Lexicon Pharmaceuticals Provides a Business and Pipeline Update at the 44th Annual J.P. Morgan Healthcare Conference SONATA-HCM on track for enrollment completion in 2026 and topline data in 2027 $10 million milestone payment triggered from licensing agreement with Novo Nordisk for LX9851 Zynquista on track for NDA resubmission and potential approval in 2026 Company presentation January 15 at 12:00 p.m. PT (3:00 p.m. ET) THE WOODLANDS, Texas, Jan. 12, 2026 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced a business and pipeline update at...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access...
Lexicon Pharmaceuticals Publishes “Relief is Possible: Ensuring Access to Effective Treatments for Chronic Pain” -White Paper based on October 2025 Roundtable of diverse stakeholders focused on accelerating innovation and expanding access to novel non-opioid therapies- -Need for swift action by policymakers to support millions of Americans suffering from chronic pain- THE WOODLANDS, Texas, Jan. 09, 2026 (GLOBE NEWSWIRE) -- In October 2025, (Nasdaq: LXRX) convened an in-person Roundtable in Washington, D.C., to better understand the unmet needs of people living with chronic pain and id...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Heal...
Lexicon Pharmaceuticals to Present at the 44th Annual J.P. Morgan Healthcare Conference THE WOODLANDS, Texas, Jan. 07, 2026 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that Company management will present at the 44th Annual J.P. Morgan Healthcare Conference on Thursday, January 15 at 12:00 p.m. PT (3:00 p.m. ET) in San Francisco. The live event and replay of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering medicines that transform patients’ live...
SiriusPoint announces expansion of IMG services following acquisition ...
SiriusPoint announces expansion of IMG services following acquisition of Assist America HAMILTON, Bermuda, Dec. 23, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced that International Medical Group (“IMG”), a leader in global insurance benefits and assistance services, and SiriusPoint’s wholly owned subsidiary, will acquire Assist America. Founded in 1990, by George W. Howard, III, Assist America is a leading provider of global emergency travel assistance services, producing around $20 m...
- Jonathan Moreland
ZEUS OLYMPIC STEEL INC.
XOMA XOMA
NWBI NORTHWEST BANCSHARES INC.
NRIM NORTHRIM BANCORP INC.
MERC MERCER INTERNATIONAL INC.
MCY MERCURY GENERAL CORPORATION
IFF INTERNATIONAL FLAVORS & FRAGRANCES INC.
CRM SALESFORCE.COM INC.
CE CELANESE CORPORATION
ARE ALEXANDRIA REAL ESTATE EQUITIES INC.
APLE APPLE HOSPITALITY REIT INC
AMH AMERICAN HOMES 4 RENT CLASS A
MGM MGM RESORTS INTERNATIONAL
OXM OXFORD INDUSTRIES INC.
RSG REPUBLIC SERVICES INC.
MHH MASTECH DIGITAL
WMG WARNER MUSIC GROUP CORP.
NHF NEXPOINT CREDIT STRATEGIES FUN
PMTS CPI CARD GROUP
NWPP NEW PEOPLES BANKSHARES INC.
MIDD THE MIDDLEBY CORPORATION
AVTR AVANTOR
SELF INC.
ALTG SELF STORAGE GROUP
IMVT INC.
ORIC ALTA EQUIPMENT GROUP INC.
NOG IMMUNOVANT INC
MRVI ORIC PHARMACEUTICALS
DMAC NORTHERN OIL AND GAS
AMR MARAVAI LIFESCIENCES HOLDINGS
NRDY DIAMEDICA THERAPEUTICS INC.
ABSI ALPHA METALLURGICAL RESOURCES INC
IMMX NERDY INC.
LUCY ABSCI CORP
LIN IMMIX BIOPHARMA INC
MNR INNOVATIVE EYEWEAR INC
XELB LINDE PUBLIC LIMITED COMPANY
FEAM MACH NATURAL RESOURCES LP
SEVN XCEL BRANDS INC.
5E ADVANCED MATERIALS INC.
SEVEN HILLS REALTY TRUST
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in t...
Lexicon Pharmaceuticals Announces Publication of Preclinical Data in the Journal of the Endocrine Society on Acyl-CoA Synthetase 5 (ACSL5) Reinforcing the Scientific Rationale for LX9851 THE WOODLANDS, Texas, Dec. 10, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced the publication of preclinical data validating Acyl-CoA Synthetase 5 (ACSL5) as a target for obesity and chronic weight management. The paper, titled “Acyl-CoA Synthetase 5 knockout and inhibitors protect against diet-induced obesity in mice by activating the ileal brake,” was published online in the . ACSL5 is an enz...
- Jonathan Moreland
NWBI NORTHWEST BANCSHARES INC.
MMLP MARTIN MIDSTREAM PARTNERS L.P.
DIN DINE BRANDS GLOBAL INC.
CRM SALESFORCE.COM INC.
CBRL CRACKER BARREL OLD COUNTRY STORE INC.
TZOO TRAVELZOO
NHF NEXPOINT CREDIT STRATEGIES FUN
DMAC DIAMEDICA THERAPEUTICS INC.
ZIP ZIPRECRUITER
NRDY INC.
LIN NERDY INC.
MXF LINDE PUBLIC LIMITED COMPANY
MDRR THE MEXICO FUND
GF INC.
CBIO MEDALIST DIVERSIFIED REIT INC.
SINT THE NEW GERMANY FUND
GMRE INC.
SEVN CRESCENT BIOPHARMA INC.
SINTX TECHNOLOGIES INC.
GLOBAL MEDICAL REIT INC.
SEVEN HILLS REALTY TRUST
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in No...
Clinical Data on Effect of Sotagliflozin on Adipose Distribution in Non-Diabetic Patients will be Presented at the 2025 Cardio Vascular Clinical Trialists Forum THE WOODLANDS, Texas, Dec. 05, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) announced clinical data on adipose tissue distribution in non-diabetic patients treated with sotagliflozin will be presented at the 22nd Global Cardio Vascular Clinical Trialists Forum (CVCT 2025). The conference is being held December 8-10, 2025, at the Mayflower Hotel in Washington, D.C. This data is from SOTA-P-CARDIA, a prospective, randomized, double-...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Invest...
Lexicon Pharmaceuticals to Participate in Two Upcoming December Investor Conferences THE WOODLANDS, Texas, Nov. 25, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference on Wednesday, December 3 at 9:00 a.m. ET and at the 8th Annual Evercore Healthcare Conference on Thursday, December 4 at 9:10 a.m. ET. The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceutic...
Moody's Ratings announces completion of a periodic review of ratings o...
Moody's Ratings (Moody's) has completed a periodic review of the ratings of BlackRock MuniYield Pennsylvania Quality Fund and other ratings that are associated with this issuer. The review was conducted through a rating committee held on 17 November 2025 in which we reassessed the appropriateness o...
SiriusPoint announces Maria Tarhanidis as Chief Investment Officer
SiriusPoint announces Maria Tarhanidis as Chief Investment Officer HAMILTON, Bermuda, Nov. 18, 2025 (GLOBE NEWSWIRE) -- SiriusPoint Ltd. (“SiriusPoint” or the “Company”) (NYSE: SPNT), a global specialty insurer and reinsurer, has today announced the appointment of Maria Tarhanidis as Chief Investment Officer, effective December 2, 2025. Based in New York, Ms. Tarhanidis will join the senior leadership team and will report to Jim McKinney, Chief Financial Officer. In her role, she will be responsible for overseeing strategic asset allocation, investment performance, and portfolio risk man...
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London He...
Lexicon Pharmaceuticals to Participate at the Jefferies 2025 London Healthcare Conference THE WOODLANDS, Texas, Nov. 11, 2025 (GLOBE NEWSWIRE) -- Lexicon Pharmaceuticals, Inc. (Nasdaq: LXRX) today announced that Company management will participate in a fireside chat at the Jefferies 2025 London Healthcare Conference on Tuesday, November 18 at 5:00 p.m. GMT (12:00 p.m. EST). The live events and replays of the presentations can be accessed via the Events page of the Company’s website at . About Lexicon Pharmaceuticals Lexicon is a biopharmaceutical company with a mission of pioneering med...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Eje...
Clinical Data Demonstrating Efficacy of Sotagliflozin in Preserved Ejection Fraction Heart Failure (HFpEF) without Diabetes Presented at American Heart Association (AHA) Annual Scientific Sessions 2025 Oral presentation highlights sotagliflozin's unique benefits to HFpEF patients in significantly improving cardiac and physical performance, and quality of life THE WOODLANDS, Texas, Nov. 08, 2025 (GLOBE NEWSWIRE) -- (Nasdaq: LXRX) today announced that new sotagliflozin clinical data was presented at the AHA Annual Scientific Sessions 2025. The data highlighted benefits observed from sot...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.